Improving the safety of iPSC-derived T cell therapy

Miki Ando; Shintaro Kinoshita; Yoshiki Furukawa; Jun Ando; Hiromitsu Nakauchi; Malcolm K. Brenner

doi:10.1016/B978-0-323-90059-1.00010-5

Improving the safety of iPSC-derived T cell therapy

Miki Ando, Shintaro Kinoshita, Yoshiki Furukawa, Jun Ando, Hiromitsu Nakauchi, Malcolm K. Brenner

Research output: Chapter in Book/Report/Conference proceeding › Chapter

4 Scopus citations

Abstract

Antigen-specific cytotoxic T lymphocyte (CTL) therapy to target and kill tumor cells induces durable remissions in selected malignancies. However, for most cancers, clinical utility is limited. CTLs continuously exposed to viral or tumor antigens, with long-term expansion, may become exhausted. Exploiting fully rejuvenated iPSC-derived antigen-specific CTLs would be a powerful approach. The chapter focuses on recent progress in engineering iPSC-derived T cells for “off-the-shelf” T cell therapy and on the importance of introducing a suicide gene safeguard system into adoptive T cell therapy, including iPSC-derived T cell therapy, to protect safety in clinical trials.

Original language	English (US)
Title of host publication	Molecular Players in iPSC Technology
Publisher	Elsevier
Pages	95-115
Number of pages	21
ISBN (Electronic)	9780323900591
DOIs	https://doi.org/10.1016/B978-0-323-90059-1.00010-5
State	Published - Jan 1 2021

Keywords

Chimeric antigen receptor T cells
Cytotoxic T lymphocytes
Inducible caspase-9
Rejuvenated T cells
Suicide-gene-based safeguard system
T-iPSCs
Virus-specific CTLs
“Off-the-shelf” T cell therapy

ASJC Scopus subject areas

Agricultural and Biological Sciences(all)
Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1016/B978-0-323-90059-1.00010-5

Cite this

@inbook{adda3810bc1d4bb4a23b63abbcd04f3e,

title = "Improving the safety of iPSC-derived T cell therapy",

abstract = "Antigen-specific cytotoxic T lymphocyte (CTL) therapy to target and kill tumor cells induces durable remissions in selected malignancies. However, for most cancers, clinical utility is limited. CTLs continuously exposed to viral or tumor antigens, with long-term expansion, may become exhausted. Exploiting fully rejuvenated iPSC-derived antigen-specific CTLs would be a powerful approach. The chapter focuses on recent progress in engineering iPSC-derived T cells for “off-the-shelf” T cell therapy and on the importance of introducing a suicide gene safeguard system into adoptive T cell therapy, including iPSC-derived T cell therapy, to protect safety in clinical trials.",

keywords = "Chimeric antigen receptor T cells, Cytotoxic T lymphocytes, Inducible caspase-9, Rejuvenated T cells, Suicide-gene-based safeguard system, T-iPSCs, Virus-specific CTLs, “Off-the-shelf” T cell therapy",

author = "Miki Ando and Shintaro Kinoshita and Yoshiki Furukawa and Jun Ando and Hiromitsu Nakauchi and Brenner, {Malcolm K.}",

year = "2021",

month = jan,

day = "1",

doi = "10.1016/B978-0-323-90059-1.00010-5",

language = "English (US)",

pages = "95--115",

booktitle = "Molecular Players in iPSC Technology",

publisher = "Elsevier",

address = "United States",

}

TY - CHAP

T1 - Improving the safety of iPSC-derived T cell therapy

AU - Ando, Miki

AU - Kinoshita, Shintaro

AU - Furukawa, Yoshiki

AU - Ando, Jun

AU - Nakauchi, Hiromitsu

AU - Brenner, Malcolm K.

PY - 2021/1/1

Y1 - 2021/1/1

N2 - Antigen-specific cytotoxic T lymphocyte (CTL) therapy to target and kill tumor cells induces durable remissions in selected malignancies. However, for most cancers, clinical utility is limited. CTLs continuously exposed to viral or tumor antigens, with long-term expansion, may become exhausted. Exploiting fully rejuvenated iPSC-derived antigen-specific CTLs would be a powerful approach. The chapter focuses on recent progress in engineering iPSC-derived T cells for “off-the-shelf” T cell therapy and on the importance of introducing a suicide gene safeguard system into adoptive T cell therapy, including iPSC-derived T cell therapy, to protect safety in clinical trials.

AB - Antigen-specific cytotoxic T lymphocyte (CTL) therapy to target and kill tumor cells induces durable remissions in selected malignancies. However, for most cancers, clinical utility is limited. CTLs continuously exposed to viral or tumor antigens, with long-term expansion, may become exhausted. Exploiting fully rejuvenated iPSC-derived antigen-specific CTLs would be a powerful approach. The chapter focuses on recent progress in engineering iPSC-derived T cells for “off-the-shelf” T cell therapy and on the importance of introducing a suicide gene safeguard system into adoptive T cell therapy, including iPSC-derived T cell therapy, to protect safety in clinical trials.

KW - Chimeric antigen receptor T cells

KW - Cytotoxic T lymphocytes

KW - Inducible caspase-9

KW - Rejuvenated T cells

KW - Suicide-gene-based safeguard system

KW - T-iPSCs

KW - Virus-specific CTLs

KW - “Off-the-shelf” T cell therapy

UR - http://www.scopus.com/inward/record.url?scp=85122815476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122815476&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-90059-1.00010-5

DO - 10.1016/B978-0-323-90059-1.00010-5

M3 - Chapter

AN - SCOPUS:85122815476

SP - 95

EP - 115

BT - Molecular Players in iPSC Technology

PB - Elsevier

ER -

Improving the safety of iPSC-derived T cell therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this